Stock Screener · Library
enGene Therapeutics Inc. financial statement history
Source-linked financial facts for enGene Therapeutics Inc. with exact reported periods, units and filing dates. Historical periods ending 2021–2025.
What this record covers
This historical reference uses a locally cached SEC companyfacts snapshot and reports periods ending from 2021 through 2025. It is not a current quotation feed, a screening recommendation or a verification of the company's present condition.
Each value retains its reported unit and exact period. Filing fiscal year describes the submitting filing and can differ from the year of a comparative fact. Values with different currencies or period boundaries are not combined.
Total assets
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| As of 2022-10-31 | 23909000 | USD | 2024-01-29 | 2023 / FY | us-gaap:Assets | 10-K · 0000950170-24-008125 |
| As of 2023-10-31 | 86959000 | USD | 2024-12-19 | 2024 / FY | us-gaap:Assets | 10-K · 0000950170-24-138472 |
| As of 2024-10-31 | 311173000 | USD | 2025-12-22 | 2025 / FY | us-gaap:Assets | 10-K · 0001193125-25-328743 |
| As of 2025-10-31 | 221468000 | USD | 2025-12-22 | 2025 / FY | us-gaap:Assets | 10-K · 0001193125-25-328743 |
Current assets
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| As of 2022-10-31 | 22583000 | USD | 2024-01-29 | 2023 / FY | us-gaap:AssetsCurrent | 10-K · 0000950170-24-008125 |
| As of 2023-10-31 | 85440000 | USD | 2024-12-19 | 2024 / FY | us-gaap:AssetsCurrent | 10-K · 0000950170-24-138472 |
| As of 2024-10-31 | 247362000 | USD | 2025-12-22 | 2025 / FY | us-gaap:AssetsCurrent | 10-K · 0001193125-25-328743 |
| As of 2025-10-31 | 201391000 | USD | 2025-12-22 | 2025 / FY | us-gaap:AssetsCurrent | 10-K · 0001193125-25-328743 |
Cash and cash equivalents
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| As of 2021-10-31 | 11017000 | USD | 2024-01-29 | 2023 / FY | us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | 10-K · 0000950170-24-008125 |
| As of 2022-10-31 | 20434000 | USD | 2024-01-29 | 2023 / FY | us-gaap:CashAndCashEquivalentsAtCarryingValue | 10-K · 0000950170-24-008125 |
| As of 2023-10-31 | 81521000 | USD | 2024-12-19 | 2024 / FY | us-gaap:CashAndCashEquivalentsAtCarryingValue | 10-K · 0000950170-24-138472 |
| As of 2024-10-31 | 173004000 | USD | 2025-12-22 | 2025 / FY | us-gaap:CashAndCashEquivalentsAtCarryingValue | 10-K · 0001193125-25-328743 |
| As of 2025-10-31 | 50152000 | USD | 2025-12-22 | 2025 / FY | us-gaap:CashAndCashEquivalentsAtCarryingValue | 10-K · 0001193125-25-328743 |
Property, plant and equipment
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| As of 2022-10-31 | 387000 | USD | 2024-01-29 | 2023 / FY | us-gaap:PropertyPlantAndEquipmentNet | 10-K · 0000950170-24-008125 |
| As of 2023-10-31 | 589000 | USD | 2024-12-19 | 2024 / FY | us-gaap:PropertyPlantAndEquipmentNet | 10-K · 0000950170-24-138472 |
| As of 2024-10-31 | 1169000 | USD | 2025-12-22 | 2025 / FY | us-gaap:PropertyPlantAndEquipmentNet | 10-K · 0001193125-25-328743 |
| As of 2025-10-31 | 2477000 | USD | 2025-12-22 | 2025 / FY | us-gaap:PropertyPlantAndEquipmentNet | 10-K · 0001193125-25-328743 |
Total liabilities
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| As of 2022-10-31 | 47405000 | USD | 2024-01-29 | 2023 / FY | us-gaap:Liabilities | 10-K · 0000950170-24-008125 |
| As of 2023-10-31 | 14473000 | USD | 2024-12-19 | 2024 / FY | us-gaap:Liabilities | 10-K · 0000950170-24-138472 |
| As of 2024-10-31 | 38561000 | USD | 2025-12-22 | 2025 / FY | us-gaap:Liabilities | 10-K · 0001193125-25-328743 |
| As of 2025-10-31 | 53758000 | USD | 2025-12-22 | 2025 / FY | us-gaap:Liabilities | 10-K · 0001193125-25-328743 |
Current liabilities
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| As of 2022-10-31 | 5104000 | USD | 2024-01-29 | 2023 / FY | us-gaap:LiabilitiesCurrent | 10-K · 0000950170-24-008125 |
| As of 2023-10-31 | 5257000 | USD | 2024-12-19 | 2024 / FY | us-gaap:LiabilitiesCurrent | 10-K · 0000950170-24-138472 |
| As of 2024-10-31 | 14661000 | USD | 2025-12-22 | 2025 / FY | us-gaap:LiabilitiesCurrent | 10-K · 0001193125-25-328743 |
| As of 2025-10-31 | 31979000 | USD | 2025-12-22 | 2025 / FY | us-gaap:LiabilitiesCurrent | 10-K · 0001193125-25-328743 |
Stockholders equity
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| As of 2021-10-31 | -53442000 | USD | 2024-01-29 | 2023 / FY | us-gaap:StockholdersEquity | 10-K · 0000950170-24-008125 |
| As of 2022-10-31 | -76614000 | USD | 2024-12-19 | 2024 / FY | us-gaap:StockholdersEquity | 10-K · 0000950170-24-138472 |
| As of 2023-10-31 | 72486000 | USD | 2025-12-22 | 2025 / FY | us-gaap:StockholdersEquity | 10-K · 0001193125-25-328743 |
| As of 2024-10-31 | 272612000 | USD | 2025-12-22 | 2025 / FY | us-gaap:StockholdersEquity | 10-K · 0001193125-25-328743 |
| As of 2025-10-31 | 167710000 | USD | 2025-12-22 | 2025 / FY | us-gaap:StockholdersEquity | 10-K · 0001193125-25-328743 |
Research and development
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| 2021-11-01 to 2022-10-31 | 15467000 | USD | 2024-01-29 | 2023 / FY | us-gaap:ResearchAndDevelopmentExpense | 10-K · 0000950170-24-008125 |
| 2022-11-01 to 2023-10-31 | 16458000 | USD | 2024-12-19 | 2024 / FY | us-gaap:ResearchAndDevelopmentExpense | 10-K · 0000950170-24-138472 |
| 2023-11-01 to 2024-10-31 | 38315000 | USD | 2025-12-22 | 2025 / FY | us-gaap:ResearchAndDevelopmentExpense | 10-K · 0001193125-25-328743 |
| 2024-11-01 to 2025-10-31 | 94480000 | USD | 2025-12-22 | 2025 / FY | us-gaap:ResearchAndDevelopmentExpense | 10-K · 0001193125-25-328743 |
Operating income
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| 2021-11-01 to 2022-10-31 | -19427000 | USD | 2024-01-29 | 2023 / FY | us-gaap:OperatingIncomeLoss | 10-K · 0000950170-24-008125 |
| 2022-11-01 to 2023-10-31 | -26060000 | USD | 2024-12-19 | 2024 / FY | us-gaap:OperatingIncomeLoss | 10-K · 0000950170-24-138472 |
| 2023-11-01 to 2024-10-31 | -62297000 | USD | 2025-12-22 | 2025 / FY | us-gaap:OperatingIncomeLoss | 10-K · 0001193125-25-328743 |
| 2024-11-01 to 2025-10-31 | -123165000 | USD | 2025-12-22 | 2025 / FY | us-gaap:OperatingIncomeLoss | 10-K · 0001193125-25-328743 |
Net income
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| 2021-11-01 to 2022-10-31 | -24462000 | USD | 2024-01-29 | 2023 / FY | us-gaap:NetIncomeLoss | 10-K · 0000950170-24-008125 |
| 2022-11-01 to 2023-10-31 | -99917000 | USD | 2024-12-19 | 2024 / FY | us-gaap:NetIncomeLoss | 10-K · 0000950170-24-138472 |
| 2023-11-01 to 2024-10-31 | -55142000 | USD | 2025-12-22 | 2025 / FY | us-gaap:NetIncomeLoss | 10-K · 0001193125-25-328743 |
| 2024-11-01 to 2025-10-31 | -117302000 | USD | 2025-12-22 | 2025 / FY | us-gaap:NetIncomeLoss | 10-K · 0001193125-25-328743 |
Diluted earnings per share
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| 2021-11-01 to 2022-10-31 | 44.3 | USD/shares | 2024-01-29 | 2023 / FY | us-gaap:EarningsPerShareDiluted | 10-K · 0000950170-24-008125 |
| 2022-11-01 to 2023-10-31 | 151.22 | USD/shares | 2024-12-19 | 2024 / FY | us-gaap:EarningsPerShareDiluted | 10-K · 0000950170-24-138472 |
| 2023-11-01 to 2024-10-31 | 1.46 | USD/shares | 2025-12-22 | 2025 / FY | us-gaap:EarningsPerShareDiluted | 10-K · 0001193125-25-328743 |
| 2024-11-01 to 2025-10-31 | 2.29 | USD/shares | 2025-12-22 | 2025 / FY | us-gaap:EarningsPerShareDiluted | 10-K · 0001193125-25-328743 |
Operating cash flow
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| 2021-11-01 to 2022-10-31 | -17592000 | USD | 2024-01-29 | 2023 / FY | us-gaap:NetCashProvidedByUsedInOperatingActivities | 10-K · 0000950170-24-008125 |
| 2022-11-01 to 2023-10-31 | -24743000 | USD | 2024-12-19 | 2024 / FY | us-gaap:NetCashProvidedByUsedInOperatingActivities | 10-K · 0000950170-24-138472 |
| 2023-11-01 to 2024-10-31 | -48281000 | USD | 2025-12-22 | 2025 / FY | us-gaap:NetCashProvidedByUsedInOperatingActivities | 10-K · 0001193125-25-328743 |
| 2024-11-01 to 2025-10-31 | -99239000 | USD | 2025-12-22 | 2025 / FY | us-gaap:NetCashProvidedByUsedInOperatingActivities | 10-K · 0001193125-25-328743 |
Capital expenditure
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| 2021-11-01 to 2022-10-31 | 153000 | USD | 2024-01-29 | 2023 / FY | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | 10-K · 0000950170-24-008125 |
| 2022-11-01 to 2023-10-31 | 318000 | USD | 2024-12-19 | 2024 / FY | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | 10-K · 0000950170-24-138472 |
| 2023-11-01 to 2024-10-31 | 925000 | USD | 2025-12-22 | 2025 / FY | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | 10-K · 0001193125-25-328743 |
| 2024-11-01 to 2025-10-31 | 1485000 | USD | 2025-12-22 | 2025 / FY | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | 10-K · 0001193125-25-328743 |
Dividends paid
| Reported period | Value | Unit | Filed | Filing FY / FP | Taxonomy concept | Source filing |
|---|---|---|---|---|---|---|
| 2022-11-01 to 2023-10-31 | 0 | USD | 2024-12-19 | 2024 / FY | us-gaap:PaymentsOfDividends | 10-K · 0000950170-24-138472 |
Source and method
SEC public numeric facts are reorganized into a standard reference. Tag priority follows the native app's declared concept chains; the latest filed observation is selected within the same exact start, end and unit. A missing value stays missing. No currency, quarterly total, ratio, share-price series or dividend calendar is inferred.
The ticker below belongs to the native source snapshot. Company names, tickers and reporting structures may change; CIK identifies the source filer.
- Source filer CIK
- 1980845
- Ticker in native snapshot
- ENGN
- Reported numeric facts
- 55
- Units present
- USD · USD/shares